menu
    • menu
    [{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Reckitt Benckiser","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Flurbiprofen","moa":"Cyclooxygenase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Reckitt Benckiser \/ Reckitt Benckiser","highestDevelopmentStatusID":"6","companyTruncated":"Reckitt Benckiser \/ Reckitt Benckiser"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reckitt Benckiser \/ Premier Research Group","highestDevelopmentStatusID":"10","companyTruncated":"Reckitt Benckiser \/ Premier Research Group"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dextromethorphan Hydrobromide","moa":"Glutamate [NMDA] receptor subunit epsilon 1 | Sigma opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reckitt Benckiser \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Reckitt Benckiser \/ Undisclosed"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Reckitt Benckiser","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"UNITED KINGDOM","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Prebiotic","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reckitt Benckiser \/ Reckitt Benckiser Group PLC","highestDevelopmentStatusID":"1","companyTruncated":"Reckitt Benckiser \/ Reckitt Benckiser Group PLC"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reckitt Benckiser \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Reckitt Benckiser \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Reckitt Benckiser

    Menu

    Reckitt Benckiser

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Reckitt Benckiser

                            United Kingdom arrow
                            FNCE
                            Not Confirmed

                            Reckitt Benckiser

                            United Kingdom arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dextromethorphan Hydrobromide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mucinex Children's Launches Mighty Chews

                            Details : Mighty Chews consisting, Dextromethorphan HBr, is the first and only over-the-counter medicated children's soft chew for cough relief.

                            Product Name : Mighty Chews

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            September 30, 2024

                            Lead Product(s) : Dextromethorphan Hydrobromide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Reckitt Benckiser

                            United Kingdom arrow
                            FNCE
                            Not Confirmed

                            Reckitt Benckiser

                            United Kingdom arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Flurbiprofen

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Recipient : University of Melbourne

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Over-the-counter NSAIDS on Cough Reflex Sensitivity in Patients with Upper Respiratory Tract Infecti...

                            Details : Flurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cough.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 21, 2023

                            Lead Product(s) : Flurbiprofen

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Recipient : University of Melbourne

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Reckitt Benckiser

                            United Kingdom arrow
                            FNCE
                            Not Confirmed

                            Reckitt Benckiser

                            United Kingdom arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibuprofen

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Phase III

                            Sponsor : Premier Research Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ibuprofen Liquid Capsules 2 x 200 mg Efficacy and PK/PD Study in Surgical Removal of Impacted Third Molars

                            Details : Ibuprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tooth, Impacted.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 02, 2022

                            Lead Product(s) : Ibuprofen

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Phase III

                            Sponsor : Premier Research Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Reckitt Benckiser

                            United Kingdom arrow
                            FNCE
                            Not Confirmed

                            Reckitt Benckiser

                            United Kingdom arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Prebiotic

                            Therapeutic Area : Sleep

                            Study Phase : Undisclosed

                            Recipient : Northumbria University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluating the Effects of Prebiotics on Sleep, the Gut Microbiome, Cognition, Immune Function and Stress

                            Details : Prebiotic is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Sleep.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            February 15, 2022

                            Lead Product(s) : Prebiotic

                            Therapeutic Area : Sleep

                            Highest Development Status : Undisclosed

                            Recipient : Northumbria University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Reckitt Benckiser

                            United Kingdom arrow
                            FNCE
                            Not Confirmed

                            Reckitt Benckiser

                            United Kingdom arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol,Ibuprofen

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Combined Paracetamol and Ibuprofen Medicine Approved for General Sale

                            Details : Nuromol is used for mild to moderate pain associated with migraine, headache, backache, period pain, dental pain, rheumatic, muscular pain, pain of non-serious arthritis, cold-flu symptoms, sore throat & fever when paracetamol or ibuprofen alone have not...

                            Product Name : Nuromol

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 16, 2021

                            Lead Product(s) : Paracetamol,Ibuprofen

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth